New drugs in acute myeloid leukemia.

Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


The acute myeloid leukemias (AML) are often fatal disorders with a range of clinical, morphologic, cytogenetic, and molecular features and a consequent need for a diverse array of therapies. This need for tailored therapy for subsets of patients with AML is exemplified in those with acute promyelocytic leukemia, the subject of a separate article in this issue (Tallman and Nabhan). Unfortunately, we tend to examine novel agents in patients with very advanced disease, in which prior therapies have inevitably altered the tumor. Of a myriad of possible exciting novel agents, a few, including PS-341, Genasense (Genta, Berkeley Heights, NJ), decitabine, 5-azacytidine, clofarabine, and troxacitabine, are briefly reviewed with an emphasis on their mechanisms of action from a perspective that suggests possible synergistic therapeutic interventions. With the growing appreciation of the pivotal role of angiogenesis in AML, angiogenesis modulators are a good example of a core class of drugs upon which future noncytotoxic combinations may be built. Those agents targeting vascular endothelial growth factor are also briefly reviewed.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalCurrent oncology reports
Issue number5
StatePublished - Sep 2002

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'New drugs in acute myeloid leukemia.'. Together they form a unique fingerprint.

Cite this